These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29275134)

  • 1. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
    Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
    Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
    Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
    Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
    Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
    Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in ocular adverse events associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study.
    Chen G; Zhang L; Zhao ST; Huang H; Fu Z
    Expert Opin Drug Saf; 2024 Jul; 23(7):877-884. PubMed ID: 38739482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.
    Jaffey JA; Leach SB; Kong LR; Wiggen KE; Bender SB; Reinero CR
    J Vet Cardiol; 2019 Aug; 24():7-19. PubMed ID: 31405557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
    Sabri MR; Bigdelian H; Hosseinzadeh M; Ahmadi A; Ghaderian M; Shoja M
    Cardiol Young; 2017 Nov; 27(9):1686-1693. PubMed ID: 28994364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
    Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE
    Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A focus on riociguat in the treatment of pulmonary arterial hypertension.
    Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
    Shiva A; Shiran M; Rafati M; Zamani H; Babazadeh K; Saeedi M; Ala S
    Drug Res (Stuttg); 2016 Jan; 66(1):7-10. PubMed ID: 25611962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
    Clavé MM; Maeda NY; Thomaz AM; Bydlowski SP; Lopes AA
    Congenit Heart Dis; 2019 Mar; 14(2):246-255. PubMed ID: 30343508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
    Chamorro V; Morales-Cano D; Milara J; Barreira B; Moreno L; Callejo M; Mondejar-Parreño G; Esquivel-Ruiz S; Cortijo J; Cogolludo Á; Barberá JA; Perez-Vizcaino F
    PLoS One; 2018; 13(1):e0191239. PubMed ID: 29364918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
    Magee AG; Makhecha S; Bentley S
    Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
    Dolladille C; Font J; Bejan-Angoulvant T; Zaman K; Sassier M; Ezine E; Stefan A; Plane AF; Legallois D; Milliez P; Parienti JJ; Alexandre J
    Arch Cardiovasc Dis; 2020; 113(6-7):420-432. PubMed ID: 32418884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.